Sanofi-Aventis's share price dropped by nearly 2% yesterday after the headline results of the Alemtuzumab trial were made public.
"Do the markets know more than we do about the results of clinical trials? Depressing if they do."
"Alemtuzumab is a very effective therapy with many advantages, but also some risks. Now that Cladribine is off the scene Alemtuzumab is the only induction therapy, or immune system rebooter, in late stage development. We need it, or should I say, I need it, as an option for treating some MS'ers who will hopefully be able to choose to go this route."
Extra reading: Alemtuzumab
Please see previous post:
02 Jun 2011
At the moment Alemtuzumab, Cladribine and bone marrow transplantation, i.e. immune system rebooters, are the only DMTs that offer the potential of a cure. All these therapies are believed to work by depleting the body of ...